Diabetic Retinopathy Management: Preparing Patients for In-Office Treatments
Overview
Optometrists play a crucial role in educating patients with diabetic retinopathy (DR) about in-office treatments such as intravitreal injections and laser photocoagulation. Proper patient preparation enhances understanding, engagement, and treatment adherence, ultimately improving outcomes and patient loyalty.
Background
Diabetic retinopathy is a common complication of diabetes that can lead to vision loss due to retinal swelling and abnormal blood vessel growth. Early diagnosis by primary eye care providers allows timely education and referral to retinal specialists for treatment. Current in-office treatments include anti-VEGF intravitreal injections, laser photocoagulation (focal, grid, and panretinal), or a combination of both. Understanding these options helps patients make informed decisions and prepares them for the treatment experience.
Data Highlights
| Treatment | Details |
|---|---|
| Intravitreal injections | 6 to 8 injections in the first year on average; <0.1% infection risk; common side effects include mild pain, floaters, redness, and light sensitivity |
| Anti-VEGF agents | Brolucizumab, bevacizumab (off-label), aflibercept-8mg, faricimab-svoa 6mg, ranibizumab, and biosimilars |
| Injection failure rate | ~20% of patients with CRT ≥300 µm or <10% CRT reduction after 3-6 injections may require treatment switch |
| Panretinal photocoagulation | Reduces risk of severe vision loss by 50%; side effects include mild ache, blurry vision, decreased peripheral and night vision |
Key Findings
- Optometrists are often the first to diagnose DR and should educate patients on treatment options to improve preparedness and engagement.
- Intravitreal anti-VEGF injections reduce macular swelling by blocking abnormal blood vessel growth; typically administered as 6-8 injections in the first year.
- About 20% of patients may not respond adequately to initial anti-VEGF therapy and may require switching agents or corticosteroid injections.
- Laser photocoagulation techniques (focal, grid, panretinal) target leaking vessels or ischemic retina to reduce swelling and prevent vision loss.
- Combination therapy with injections followed by laser can be used to address both macular swelling and abnormal vessel proliferation.
- Patient education should include procedure expectations, potential side effects, and signs of complications to ensure timely management.
Clinical Implications
Providing patients with clear, detailed education about diabetic retinopathy treatments facilitates informed consent and improves adherence to therapy. Utilizing supporting documentation and involving allied staff in patient education can enhance understanding and retention. Monitoring for treatment response and complications is essential to optimize outcomes and adjust therapy as needed.
Conclusion
Effective patient preparation by optometrists through education on intravitreal injections and laser treatments enhances the diabetic retinopathy care pathway. This approach supports better patient experiences, treatment adherence, and visual outcomes.
References
- Elman MJ et al. 2015 -- Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.